{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:56Z","timestamp":1792511936459,"version":"4.5.0"},"reference-count":227,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02687-4","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:01:07Z","timestamp":1785110467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mucosal immunity and vaccine development"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-2301","authenticated-orcid":false,"given":"Weiqi","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-0120","authenticated-orcid":false,"given":"Aqu","family":"Alu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"2687_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/imm.13526","volume":"167","author":"VA Correa","year":"2022","unstructured":"Correa, V. A., Portilho, A. I. & De Gaspari, E. Vaccines, adjuvants and key factors for mucosal immune response. Immunology. 167, 124\u2013138 (2022).","journal-title":"Immunology"},{"key":"2687_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00654-6","volume":"8","author":"JM Knisely","year":"2023","unstructured":"Knisely, J. M. et al. Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-workshop report. NPJ. Vaccines. 8, 53 (2023).","journal-title":"NPJ. Vaccines"},{"key":"2687_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.imlet.2019.10.013","volume":"217","author":"M Li","year":"2020","unstructured":"Li, M. et al. Mucosal vaccines: strategies and challenges. Immunol. Lett. 217, 116\u2013125 (2020).","journal-title":"Immunol. Lett."},{"key":"2687_CR4","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/nm1213","volume":"11","author":"J Holmgren","year":"2005","unstructured":"Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 11, S45\u2013S53 (2005).","journal-title":"Nat. Med."},{"key":"2687_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","volume":"22","author":"EC Lavelle","year":"2022","unstructured":"Lavelle, E. C. & Ward, R. W. Mucosal vaccines\u2014fortifying the frontiers. Nat. Rev. Immunol. 22, 236\u2013250 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2687_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70056","volume":"6","author":"M Zhou","year":"2025","unstructured":"Zhou, M. et al. Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications. MedComm. 6, e70056 (2025).","journal-title":"MedComm"},{"key":"2687_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201903847","volume":"32","author":"S Ferber","year":"2020","unstructured":"Ferber, S. et al. Immunology-guided biomaterial design for mucosal cancer vaccines. Adv. Mater. 32, e1903847 (2020).","journal-title":"Adv. Mater."},{"key":"2687_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/vaccines12020191","volume":"12","author":"Y Song","year":"2024","unstructured":"Song, Y., Mehl, F. & Zeichner, S. L. Vaccine strategies to elicit mucosal immunity. Vaccines. 12, 191 (2024).","journal-title":"Vaccines"},{"key":"2687_CR9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3390\/vaccines11101585","volume":"11","author":"F Dotiwala","year":"2023","unstructured":"Dotiwala, F. & Upadhyay, A. K. Next generation mucosal vaccine strategy for respiratory pathogens. Vaccines 11, 1585 (2023).","journal-title":"Vaccines"},{"key":"2687_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14760584.2023.2268724","volume":"22","author":"CJY Tsai","year":"2023","unstructured":"Tsai, C. J. Y., Loh, J. M. S., Fujihashi, K. & Kiyono, H. Mucosal vaccination: onward and upward. Expert Rev. Vaccines 22, 885\u2013899 (2023).","journal-title":"Expert Rev. Vaccines"},{"key":"2687_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/path.4843","volume":"241","author":"HM Mitchison","year":"2017","unstructured":"Mitchison, H. M. & Valente, E. M. Motile and non-motile cilia in human pathology: from function to phenotypes. J. Pathol. 241, 294\u2013309 (2017).","journal-title":"J. Pathol."},{"key":"2687_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.addr.2015.03.007","volume":"91","author":"CJ Davitt","year":"2015","unstructured":"Davitt, C. J. & Lavelle, E. C. Delivery strategies to enhance oral vaccination against enteric infections. Adv. Drug Deliv. Rev. 91, 52\u201369 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2687_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174304","volume":"134","author":"W Ren","year":"2024","unstructured":"Ren, W. et al. SARS-CoV-2 Delta and Omicron variants resist spike cleavage by human airway trypsin-like protease. J. Clin. Investig. 134, e174304 (2024).","journal-title":"J. Clin. Investig."},{"key":"2687_CR14","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1002\/eji.201343782","volume":"43","author":"Y Kurashima","year":"2013","unstructured":"Kurashima, Y., Goto, Y. & Kiyono, H. Mucosal innate immune cells regulate both gut homeostasis and intestinal inflammation. Eur. J. Immunol. 43, 3108\u20133115 (2013).","journal-title":"Eur. J. Immunol."},{"key":"2687_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/mi.2013.30","volume":"6","author":"NA Mabbott","year":"2013","unstructured":"Mabbott, N. A. et al. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 6, 666\u2013677 (2013).","journal-title":"Mucosal Immunol."},{"key":"2687_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10144-w","volume":"10","author":"RJ Komban","year":"2019","unstructured":"Komban, R. J. et al. Activated Peyer\u2019s patch B cells sample antigen directly from M cells in the subepithelial dome. Nat. Commun. 10, 2423 (2019).","journal-title":"Nat. Commun."},{"key":"2687_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.molmed.2022.10.009","volume":"29","author":"R Nakahashi-Ouchida","year":"2023","unstructured":"Nakahashi-Ouchida, R. et al. Nasal vaccines: solutions for respiratory infectious diseases. Trends Mol. Med. 29, 124\u2013140 (2023).","journal-title":"Trends Mol. Med."},{"key":"2687_CR18","doi-asserted-by":"crossref","unstructured":"Krishnaswamy, J. K. et al. Migratory CD11b(+) conventional dendritic cells induce T follicular helper cell-dependent antibody responses. Sci. Immunol. 2, eaam9169 (2017).","DOI":"10.1126\/sciimmunol.aam9169"},{"key":"2687_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4049\/jimmunol.182.1.5","volume":"182","author":"J Stavnezer","year":"2009","unstructured":"Stavnezer, J. & Kang, J. The surprising discovery that TGF beta specifically induces the IgA class switch. J. Immunol. 182, 5\u20137 (2009).","journal-title":"J. Immunol."},{"key":"2687_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fimmu.2014.00065","volume":"5","author":"L Moens","year":"2014","unstructured":"Moens, L. & Tangye, S. G. Cytokine-mediated regulation of plasma cell generation: IL-21 takes center stage. Front. Immunol. 5, 65 (2014).","journal-title":"Front. Immunol."},{"key":"2687_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.7774\/cevr.2022.11.3.235","volume":"11","author":"R Anggraeni","year":"2022","unstructured":"Anggraeni, R., Ana, I. D. & Wihadmadyatami, H. Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants. Clin. Exp. Vaccine Res. 11, 235\u2013248 (2022).","journal-title":"Clin. Exp. Vaccine Res."},{"key":"2687_CR22","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3390\/ijms22052284","volume":"22","author":"H Wei","year":"2021","unstructured":"Wei, H. & Wang, J. Y. Role of polymeric immunoglobulin receptor in IgA and IgM transcytosis. Int. J. Mol. Sci. 22, 2284 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2687_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41577-019-0261-1","volume":"20","author":"K Chen","year":"2020","unstructured":"Chen, K., Magri, G., Grasset, E. K. & Cerutti, A. Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA. Nat. Rev. Immunol. 20, 427\u2013441 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2687_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175233","volume":"135","author":"Y Lin","year":"2025","unstructured":"Lin, Y. et al. Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2. J. Clin. Investig. 135, e175233 (2025).","journal-title":"J. Clin. Investig."},{"key":"2687_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jaci.2010.09.026","volume":"126","author":"I Puga","year":"2010","unstructured":"Puga, I., Cols, M. & Cerutti, A. Innate signals in mucosal immunoglobulin class switching. J. Allergy Clin. Immunol. 126, 889\u2013895 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2687_CR26","doi-asserted-by":"publisher","first-page":"e2250085","DOI":"10.1002\/eji.202250085","volume":"53","author":"L Reusch","year":"2023","unstructured":"Reusch, L. & Angeletti, D. Memory B-cell diversity: from early generation to tissue residency and reactivation. Eur. J. Immunol. 53, e2250085 (2023).","journal-title":"Eur. J. Immunol."},{"key":"2687_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-024-07748-8","volume":"632","author":"SI Ramirez","year":"2024","unstructured":"Ramirez, S. I. et al. Immunological memory diversity in the human upper airway. Nature 632, 630\u2013636 (2024).","journal-title":"Nature"},{"key":"2687_CR28","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1182\/blood.2019002782","volume":"136","author":"NM Weisel","year":"2020","unstructured":"Weisel, N. M. et al. Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype. Blood 136, 2774\u20132785 (2020).","journal-title":"Blood"},{"key":"2687_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","volume":"20","author":"SR Allie","year":"2019","unstructured":"Allie, S. R. et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol. 20, 97\u2013108 (2019).","journal-title":"Nat. Immunol."},{"key":"2687_CR30","doi-asserted-by":"publisher","first-page":"953088","DOI":"10.3389\/fimmu.2022.953088","volume":"13","author":"CM Lee","year":"2022","unstructured":"Lee, C. M. & Oh, J. E. Resident memory B cells in barrier tissues. Front Immunol. 13, 953088 (2022).","journal-title":"Front Immunol."},{"key":"2687_CR31","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.immuni.2022.06.002","volume":"55","author":"C Gregoire","year":"2022","unstructured":"Gregoire, C. et al. Viral infection engenders bona fide and bystander subsets of lung-resident memory B cells through a permissive mechanism. Immunity 55, 1216\u20131233.e1219 (2022).","journal-title":"Immunity"},{"key":"2687_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/antib8040057","volume":"8","author":"P de Sousa-Pereira","year":"2019","unstructured":"de Sousa-Pereira, P. & Woof, J. M. IgA: structure, function, and developability. Antibodies. 8, 57 (2019).","journal-title":"Antibodies"},{"key":"2687_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.hlife.2023.12.005","volume":"2","author":"Y Lin","year":"2024","unstructured":"Lin, Y., Hu, Z., Fu, Y.-X. & Peng, H. Mucosal vaccine development for respiratory viral infections. hLife 2, 50\u201363 (2024).","journal-title":"hLife"},{"key":"2687_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1051\/vetres:2006010","volume":"37","author":"V Snoeck","year":"2006","unstructured":"Snoeck, V., Peters, I. R. & Cox, E. The IgA system: a comparison of structure and function in different species. Vet. Res. 37, 455\u2013467 (2006).","journal-title":"Vet. Res."},{"key":"2687_CR35","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.4049\/jimmunol.163.10.5367","volume":"163","author":"S Shimada","year":"1999","unstructured":"Shimada, S. et al. Generation of polymeric immunoglobulin receptor-deficient mouse with marked reduction of secretory IgA. J. Immunol. 163, 5367\u20135373 (1999).","journal-title":"J. Immunol."},{"key":"2687_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1555","volume":"13","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2687_CR37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22058","volume":"544","author":"K Moor","year":"2017","unstructured":"Moor, K. et al. High-avidity IgA protects the intestine by enchaining growing bacteria. Nature 544, 498\u2013502 (2017).","journal-title":"Nature"},{"key":"2687_CR38","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-024-01906-0","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies. Signal Transduct. Target. Ther. 9, 190 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2687_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.hlife.2024.05.004","volume":"2","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasion. hLife 2, 488\u2013491 (2024).","journal-title":"hLife"},{"key":"2687_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41575-021-00563-w","volume":"19","author":"O Pabst","year":"2022","unstructured":"Pabst, O. & Izcue, A. Secretory IgA: controlling the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 19, 149\u2013150 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2687_CR41","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/14760584.2024.2326094","volume":"23","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines. Expert Rev. Vaccines 23, 362\u2013370 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"2687_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","volume":"10","author":"F Zhu","year":"2022","unstructured":"Zhu, F. et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir. Med. 10, 749\u2013760 (2022).","journal-title":"Lancet Respir. Med."},{"key":"2687_CR43","doi-asserted-by":"publisher","first-page":"104298","DOI":"10.1016\/j.ebiom.2022.104298","volume":"85","author":"M Madhavan","year":"2022","unstructured":"Madhavan, M. et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial. EBioMedicine. 85, 104298 (2022).","journal-title":"EBioMedicine"},{"key":"2687_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nri.2015.3","volume":"16","author":"SN Mueller","year":"2016","unstructured":"Mueller, S. N. & Mackay, L. K. Tissue-resident memory T cells: local specialists in immune defence. Nat. Rev. Immunol. 16, 79\u201389 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2687_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo5871","volume":"8","author":"S Yenyuwadee","year":"2022","unstructured":"Yenyuwadee, S. et al. The evolving role of tissue-resident memory T cells in infections and cancer. Sci. Adv. 8, eabo5871 (2022).","journal-title":"Sci. Adv."},{"key":"2687_CR46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41577-023-00853-1","volume":"23","author":"E Rotrosen","year":"2023","unstructured":"Rotrosen, E. & Kupper, T. S. Assessing the generation of tissue resident memory T cells by vaccines. Nat. Rev. Immunol. 23, 655\u2013665 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2687_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-immunol-101320-020220","volume":"42","author":"SN Christo","year":"2024","unstructured":"Christo, S. N., Park, S. L., Mueller, S. N. & Mackay, L. K. The multifaceted role of tissue-resident memory T cells. Annu. Rev. Immunol. 42, 317\u2013345 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"2687_CR48","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.immuni.2014.12.007","volume":"41","author":"JM Schenkel","year":"2014","unstructured":"Schenkel, J. M. & Masopust, D. Tissue-resident memory T cells. Immunity. 41, 886\u2013897 (2014).","journal-title":"Immunity"},{"key":"2687_CR49","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.celrep.2017.08.078","volume":"20","author":"BV Kumar","year":"2017","unstructured":"Kumar, B. V. et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 20, 2921\u20132934 (2017).","journal-title":"Cell Rep."},{"key":"2687_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abb6808","volume":"6","author":"N Swarnalekha","year":"2021","unstructured":"Swarnalekha, N. et al. T resident helper cells promote humoral responses in the lung. Sci. Immunol. 6, eabb6808 (2021).","journal-title":"Sci. Immunol."},{"key":"2687_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abb6852","volume":"6","author":"YM Son","year":"2021","unstructured":"Son, Y. M. et al. Tissue-resident CD4(+) T helper cells assist the development of protective respiratory B and CD8(+) T cell memory responses. Sci. Immunol. 6, eabb6852 (2021).","journal-title":"Sci. Immunol."},{"key":"2687_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aag2031","volume":"2","author":"B Sl\u00fctter","year":"2017","unstructured":"Sl\u00fctter, B. et al. Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity. Sci. Immunol. 2, eaag2031 (2017).","journal-title":"Sci. Immunol."},{"key":"2687_CR53","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192197","volume":"217","author":"JM Stolley","year":"2020","unstructured":"Stolley, J. M. et al. Retrograde migration supplies resident memory T cells to lung-draining LN after influenza infection. J. Exp. Med. 217, e20192197 (2020).","journal-title":"J. Exp. Med."},{"key":"2687_CR54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41385-020-0309-3","volume":"14","author":"I Uddb\u00e4ck","year":"2021","unstructured":"Uddb\u00e4ck, I. et al. Long-term maintenance of lung resident memory T cells is mediated by persistent antigen. Mucosal Immunol. 14, 92\u201399 (2021).","journal-title":"Mucosal Immunol."},{"key":"2687_CR55","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.chom.2023.10.015","volume":"31","author":"A Ziogas","year":"2023","unstructured":"Ziogas, A. et al. Trained immunity: Target for prophylaxis and therapy. Cell Host Microbe 31, 1776\u20131791 (2023).","journal-title":"Cell Host Microbe"},{"key":"2687_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.chom.2012.06.006","volume":"12","author":"J Quintin","year":"2012","unstructured":"Quintin, J. et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12, 223\u2013232 (2012).","journal-title":"Cell Host Microbe"},{"key":"2687_CR57","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1016\/j.celrep.2019.08.004","volume":"28","author":"JC Dos Santos","year":"2019","unstructured":"Dos Santos, J. C. et al. \u03b2-glucan-induced trained immunity protects against Leishmania braziliensis infection: a crucial role for IL-32. Cell Rep. 28, 2659\u20132672.e2656 (2019).","journal-title":"Cell Rep."},{"key":"2687_CR58","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.chom.2023.05.004","volume":"31","author":"MG Netea","year":"2023","unstructured":"Netea, M. G. et al. The role of trained immunity in COVID-19: lessons for the next pandemic. Cell Host Microbe. 31, 890\u2013901 (2023).","journal-title":"Cell Host Microbe"},{"key":"2687_CR59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375\u2013388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2687_CR60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2020.10.011","volume":"54","author":"S Fanucchi","year":"2021","unstructured":"Fanucchi, S. et al. The intersection of epigenetics and metabolism in trained immunity. Immunity 54, 32\u201343 (2021).","journal-title":"Immunity"},{"key":"2687_CR61","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1146\/annurev-immunol-102119-073855","volume":"39","author":"S Bekkering","year":"2021","unstructured":"Bekkering, S. et al. Trained immunity: reprogramming innate immunity in health and disease. Annu. Rev. Immunol. 39, 667\u2013693 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"2687_CR62","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/imr.13326","volume":"323","author":"P Vuscan","year":"2024","unstructured":"Vuscan, P., Kischkel, B., Joosten, L. A. B. & Netea, M. G. Trained immunity: general and emerging concepts. Immunol. Rev. 323, 164\u2013185 (2024).","journal-title":"Immunol. Rev."},{"key":"2687_CR63","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.1202870109","volume":"109","author":"J Kleinnijenhuis","year":"2012","unstructured":"Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA 109, 17537\u201317542 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2687_CR64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","volume":"23","author":"RJW Arts","year":"2018","unstructured":"Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89\u2013100.e105 (2018).","journal-title":"Cell Host Microbe"},{"key":"2687_CR65","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157393","volume":"7","author":"BZ Zhang","year":"2022","unstructured":"Zhang, B. Z. et al. Bacillus Calmette-Gu\u00e9rin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. JCI Insight 7, e157393 (2022).","journal-title":"JCI Insight"},{"key":"2687_CR66","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","volume":"20","author":"LAJ O\u2019Neill","year":"2020","unstructured":"O\u2019Neill, L. A. J. & Netea, M. G. BCG-induced trained immunity: can it offer protection against COVID-19?. Nat. Rev. Immunol. 20, 335\u2013337 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2687_CR67","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.cell.2018.09.042","volume":"175","author":"Y Yao","year":"2018","unstructured":"Yao, Y. et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell 175, 1634\u20131650.e1617 (2018).","journal-title":"Cell"},{"key":"2687_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39560-9","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters. Nat. Commun. 14, 4117 (2023).","journal-title":"Nat. Commun."},{"key":"2687_CR69","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.cell.2018.11.007","volume":"175","author":"MG Netea","year":"2018","unstructured":"Netea, M. G. & Joosten, L. A. B. Trained immunity and local innate immune memory in the lung. Cell 175, 1463\u20131465 (2018).","journal-title":"Cell"},{"key":"2687_CR70","doi-asserted-by":"publisher","first-page":"103841","DOI":"10.1016\/j.ebiom.2022.103841","volume":"76","author":"A Alu","year":"2022","unstructured":"Alu, A. et al. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine 76, 103841 (2022).","journal-title":"EBioMedicine"},{"key":"2687_CR71","doi-asserted-by":"publisher","first-page":"114021","DOI":"10.1016\/j.addr.2021.114021","volume":"179","author":"Y Lee","year":"2021","unstructured":"Lee, Y., Kamada, N. & Moon, J. J. Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome. Adv. Drug Deliv. Rev. 179, 114021 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2687_CR72","doi-asserted-by":"publisher","first-page":"2045853","DOI":"10.1080\/21645515.2022.2045853","volume":"18","author":"K Dhama","year":"2022","unstructured":"Dhama, K. et al. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum. Vaccines Immunother. 18, 2045853 (2022).","journal-title":"Hum. Vaccines Immunother."},{"key":"2687_CR73","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.vaccine.2021.03.006","volume":"39","author":"Y Du","year":"2021","unstructured":"Du, Y. et al. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse. Vaccine 39, 2280\u20132287 (2021).","journal-title":"Vaccine"},{"key":"2687_CR74","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2016.05.001","volume":"233","author":"CJ Davitt","year":"2016","unstructured":"Davitt, C. J. et al. A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens. J. Control. Release 233, 162\u2013173 (2016).","journal-title":"J. Control. Release"},{"key":"2687_CR75","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","volume":"26","author":"VP Chavda","year":"2021","unstructured":"Chavda, V. P., Vora, L. K., Pandya, A. K. & Patravale, V. B. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov. Today 26, 2619\u20132636 (2021).","journal-title":"Drug Discov. Today"},{"key":"2687_CR76","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/nnm.14.123","volume":"10","author":"J Singh","year":"2015","unstructured":"Singh, J. et al. Development of amino acid substituted gemini surfactant-based mucoadhesive gene delivery systems for potential use as noninvasive vaginal genetic vaccination. Nanomedicine 10, 405\u2013417 (2015).","journal-title":"Nanomedicine"},{"key":"2687_CR77","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1285-1","volume":"571","author":"JE Oh","year":"2019","unstructured":"Oh, J. E. et al. Migrant memory B cells secrete luminal antibody in the vagina. Nature 571, 122\u2013126 (2019).","journal-title":"Nature"},{"key":"2687_CR78","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/mi.2017.89","volume":"11","author":"HX Tan","year":"2018","unstructured":"Tan, H. X. et al. Induction of vaginal-resident HIV-specific CD8 T cells with mucosal prime-boost immunization. Mucosal Immunol. 11, 994\u20131007 (2018).","journal-title":"Mucosal Immunol."},{"key":"2687_CR79","doi-asserted-by":"crossref","unstructured":"Thakur, A. & Foged, C. Nanoparticles for mucosal vaccine delivery. In Nanoengineered Biomaterials for Advanced Drug Delivery (ed. Mozafari, M.) 603\u2013646 (Elsevier, 2020).","DOI":"10.1016\/B978-0-08-102985-5.00025-5"},{"key":"2687_CR80","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.vaccine.2017.11.008","volume":"36","author":"B Sahay","year":"2018","unstructured":"Sahay, B. et al. Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex. Vaccine 36, 155\u2013164 (2018).","journal-title":"Vaccine"},{"key":"2687_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.539","volume":"5","author":"W Hong","year":"2024","unstructured":"Hong, W. et al. A chimeric adenovirus-vectored vaccine based on Beta spike and Delta RBD confers a broad-spectrum neutralization against Omicron-included SARS-CoV-2 variants. MedComm 5, e539 (2024).","journal-title":"MedComm"},{"key":"2687_CR82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102775118","volume":"118","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc. Natl. Acad. Sci. USA 118, e2102775118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2687_CR83","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","volume":"15","author":"A Fathi","year":"2019","unstructured":"Fathi, A., Dahlke, C. & Addo, M. M. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Hum. Vaccines Immunother. 15, 2269\u20132285 (2019).","journal-title":"Hum. Vaccines Immunother."},{"key":"2687_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1965","volume":"28","author":"Z Chen","year":"2018","unstructured":"Chen, Z. Parainfluenza virus 5-vectored vaccines against human and animal infectious diseases. Rev. Med. Virol. 28, e1965 (2018).","journal-title":"Rev. Med. Virol."},{"key":"2687_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00503-y","volume":"7","author":"T Travieso","year":"2022","unstructured":"Travieso, T. et al. The use of viral vectors in vaccine development. NPJ Vaccines 7, 75 (2022).","journal-title":"NPJ Vaccines"},{"key":"2687_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","volume":"184","author":"K Ganar","year":"2014","unstructured":"Ganar, K., Das, M., Sinha, S. & Kumar, S. Newcastle disease virus: current status and our understanding. Virus Res. 184, 71\u201381 (2014).","journal-title":"Virus Res."},{"key":"2687_CR87","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","volume":"24","author":"S Su","year":"2016","unstructured":"Su, S. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24, 490\u2013502 (2016).","journal-title":"Trends Microbiol."},{"key":"2687_CR88","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrmicro.2016.46","volume":"14","author":"SM McDonald","year":"2016","unstructured":"McDonald, S. M., Nelson, M. I., Turner, P. E. & Patton, J. T. Reassortment in segmented RNA viruses: mechanisms and outcomes. Nat. Rev. Microbiol. 14, 448\u2013460 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"2687_CR89","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/14760584.2019.1582338","volume":"18","author":"T Gerlach","year":"2019","unstructured":"Gerlach, T., Elbahesh, H., Saletti, G. & Rimmelzwaan, G. F. Recombinant influenza A viruses as vaccine vectors. Expert Rev. Vaccines 18, 379\u2013392 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"2687_CR90","doi-asserted-by":"publisher","first-page":"100432","DOI":"10.1016\/j.dmpk.2021.100432","volume":"42","author":"F Sakurai","year":"2022","unstructured":"Sakurai, F., Tachibana, M. & Mizuguchi, H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab. Pharmacokinetics 42, 100432 (2022).","journal-title":"Drug Metab. Pharmacokinetics"},{"key":"2687_CR91","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct. Target. Ther. 8, 149 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2687_CR92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140794","volume":"131","author":"K Matsuda","year":"2021","unstructured":"Matsuda, K. et al. A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. J. Clin. Investig. 131, e140794 (2021).","journal-title":"J. Clin. Investig."},{"key":"2687_CR93","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155655","volume":"7","author":"M Jeyanathan","year":"2022","unstructured":"Jeyanathan, M. et al. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight. 7, e155655 (2022).","journal-title":"JCI Insight"},{"key":"2687_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.920256","volume":"13","author":"C Maier","year":"2022","unstructured":"Maier, C. et al. Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity. Front. Immunol. 13, 920256 (2022).","journal-title":"Front. Immunol."},{"key":"2687_CR95","doi-asserted-by":"publisher","first-page":"104585","DOI":"10.1016\/j.ebiom.2023.104585","volume":"92","author":"D Pilapitiya","year":"2023","unstructured":"Pilapitiya, D., Wheatley, A. K. & Tan, H. X. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine. 92, 104585 (2023).","journal-title":"EBioMedicine"},{"key":"2687_CR96","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"S Wu","year":"2021","unstructured":"Wu, S. et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect. Dis. 21, 1654\u20131664 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"2687_CR97","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1080\/22221751.2022.2119169","volume":"11","author":"AI Tukhvatulin","year":"2022","unstructured":"Tukhvatulin, A. I. et al. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerg. microbes Infect. 11, 2229\u20132247 (2022).","journal-title":"Emerg. microbes Infect."},{"key":"2687_CR98","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/vaccines11020432","volume":"11","author":"VP Chavda","year":"2023","unstructured":"Chavda, V. P. et al. Adenoviral vector-based vaccine platform for COVID-19: current status. Vaccines 11, 432 (2023).","journal-title":"Vaccines"},{"key":"2687_CR99","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1016\/j.vaccine.2024.04.054","volume":"42","author":"J Kim","year":"2024","unstructured":"Kim, J. & Chang, J. Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2. Vaccine 42, 3505\u20133513 (2024).","journal-title":"Vaccine"},{"key":"2687_CR100","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1128\/JVI.02864-12","volume":"87","author":"JS Richardson","year":"2013","unstructured":"Richardson, J. S., Pillet, S., Bello, A. J. & Kobinger, G. P. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J. Virol. 87, 3668\u20133677 (2013).","journal-title":"J. Virol."},{"key":"2687_CR101","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.180784","volume":"9","author":"B Sun","year":"2024","unstructured":"Sun, B. et al. An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA. JCI Insight 9, e180784 (2024).","journal-title":"JCI Insight"},{"key":"2687_CR102","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/mtm.2016.30","volume":"3","author":"S Afkhami","year":"2016","unstructured":"Afkhami, S., Yao, Y. & Xing, Z. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol. Ther. Methods Clin. Dev. 3, 16030 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2687_CR103","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184.e113 (2020).","journal-title":"Cell"},{"key":"2687_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00717-8","volume":"8","author":"C Singh","year":"2023","unstructured":"Singh, C. et al. Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin(\u00ae)). NPJ Vaccines 8, 125 (2023).","journal-title":"NPJ Vaccines"},{"key":"2687_CR105","doi-asserted-by":"publisher","first-page":"eabh0755","DOI":"10.1126\/scitranslmed.abh0755","volume":"13","author":"N van Doremalen","year":"2021","unstructured":"van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci. Transl. Med. 13, eabh0755 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2687_CR106","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S2213-2600(23)00349-1","volume":"11","author":"F Zhu","year":"2023","unstructured":"Zhu, F. et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 1075\u20131088 (2023).","journal-title":"Lancet Respir. Med."},{"key":"2687_CR107","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.scib.2022.05.018","volume":"67","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci. Bull. 67, 1372\u20131387 (2022).","journal-title":"Sci. Bull."},{"key":"2687_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00662-6","volume":"8","author":"S Ponce-de-Le\u00f3n","year":"2023","unstructured":"Ponce-de-Le\u00f3n, S. et al. Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. NPJ Vaccines 8, 67 (2023).","journal-title":"NPJ Vaccines"},{"key":"2687_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00509-6","volume":"7","author":"MF Tioni","year":"2022","unstructured":"Tioni, M. F. et al. Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2. NPJ Vaccines 7, 85 (2022).","journal-title":"NPJ Vaccines"},{"key":"2687_CR110","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi5246","volume":"7","author":"D An","year":"2021","unstructured":"An, D. et al. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. Sci. Adv. 7, eabi5246 (2021).","journal-title":"Sci. Adv."},{"key":"2687_CR111","doi-asserted-by":"crossref","unstructured":"Loes, A. N. et al. Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. Viruses 12, 987 (2020).","DOI":"10.3390\/v12090987"},{"key":"2687_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103379","volume":"24","author":"J Ohtsuka","year":"2021","unstructured":"Ohtsuka, J. et al. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. iScience 24, 103379 (2021).","journal-title":"iScience"},{"key":"2687_CR113","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.chom.2020.12.010","volume":"29","author":"MW Ku","year":"2021","unstructured":"Ku, M. W. et al. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe 29, 236\u2013249.e236 (2021).","journal-title":"Cell Host Microbe"},{"key":"2687_CR114","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114459","volume":"13","author":"MW Ku","year":"2021","unstructured":"Ku, M. W. et al. Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice. EMBO Mol. Med. 13, e14459 (2021).","journal-title":"EMBO Mol. Med."},{"key":"2687_CR115","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41392-021-00797-9","volume":"6","author":"H Li","year":"2021","unstructured":"Li, H. et al. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Transduct. Target. Ther. 6, 389 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2687_CR116","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/vaccines12091001","volume":"12","author":"G Lemos-P\u00e9rez","year":"2024","unstructured":"Lemos-P\u00e9rez, G. et al. Safety and immunogenicity of the intranasal vaccine candidate mambisa and the intramuscular vaccine abdala used as booster doses for COVID-19 convalescents: a randomized phase 1-2 clinical trial. Vaccines 12, 1001 (2024).","journal-title":"Vaccines"},{"key":"2687_CR117","doi-asserted-by":"publisher","first-page":"16757","DOI":"10.1021\/acsnano.2c06350","volume":"16","author":"JH Lam","year":"2022","unstructured":"Lam, J. H. et al. Artificial cell membrane polymersome-based intranasal beta spike formulation as a second generation Covid-19 vaccine. ACS Nano 16, 16757\u201316775 (2022).","journal-title":"ACS Nano"},{"key":"2687_CR118","doi-asserted-by":"publisher","first-page":"836745","DOI":"10.3389\/fimmu.2022.836745","volume":"13","author":"SR Banihashemi","year":"2022","unstructured":"Banihashemi, S. R. et al. Safety and efficacy of combined intramuscular\/intranasal RAZI-COV PARS vaccine candidate against SARS-CoV-2: a preclinical study in several animal models. Front. Immunol. 13, 836745 (2022).","journal-title":"Front. Immunol."},{"key":"2687_CR119","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/vaccines11020455","volume":"11","author":"MS Dodaran","year":"2023","unstructured":"Dodaran, M. S. et al. Immunogenicity and safety of a combined intramuscular\/intranasal recombinant spike protein COVID-19 vaccine (RCP) in healthy adults aged 18 to 55 years old: a randomized, double-blind, placebo-controlled, phase I trial. Vaccines 11, 455 (2023).","journal-title":"Vaccines"},{"key":"2687_CR120","doi-asserted-by":"publisher","first-page":"110026","DOI":"10.1016\/j.virol.2024.110026","volume":"593","author":"B Ma","year":"2024","unstructured":"Ma, B. et al. Mucosal vaccines for viral diseases: status and prospects. Virology 593, 110026 (2024).","journal-title":"Virology"},{"key":"2687_CR121","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jconrel.2023.02.011","volume":"355","author":"X He","year":"2023","unstructured":"He, X. et al. Recent advances in respiratory immunization: a focus on COVID-19 vaccines. J. Control. Release 355, 655\u2013674 (2023).","journal-title":"J. Control. Release"},{"key":"2687_CR122","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1056\/NEJMp048006","volume":"350","author":"RB Couch","year":"2004","unstructured":"Couch, R. B. Nasal vaccination, Escherichia coli enterotoxin, and Bell\u2019s palsy. N. Engl. J. Med. 350, 860\u2013861 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2687_CR123","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.vaccine.2016.03.002","volume":"34","author":"M Lebens","year":"2016","unstructured":"Lebens, M. et al. Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae. Vaccine 34, 2121\u20132128 (2016).","journal-title":"Vaccine"},{"key":"2687_CR124","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/mi.2010.54","volume":"3","author":"N Lycke","year":"2010","unstructured":"Lycke, N. & Bemark, M. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol. 3, 556\u2013566 (2010).","journal-title":"Mucosal Immunol."},{"key":"2687_CR125","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.vaccine.2019.02.006","volume":"37","author":"SC Pan","year":"2019","unstructured":"Pan, S. C. et al. A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(\u03b1K): a phase I study. Vaccine 37, 1994\u20132003 (2019).","journal-title":"Vaccine"},{"key":"2687_CR126","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.vaccine.2010.11.091","volume":"29","author":"VP da Hora","year":"2011","unstructured":"da Hora, V. P., Concei\u00e7\u00e3o, F. R., Dellagostin, O. A. & Doolan, D. L. Non-toxic derivatives of LT as potent adjuvants. Vaccine 29, 1538\u20131544 (2011).","journal-title":"Vaccine"},{"key":"2687_CR127","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.vaccine.2015.03.096","volume":"33","author":"D Newsted","year":"2015","unstructured":"Newsted, D., Fallahi, F., Golshani, A. & Azizi, A. Advances and challenges in mucosal adjuvant technology. Vaccine 33, 2399\u20132405 (2015).","journal-title":"Vaccine"},{"key":"2687_CR128","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.vaccine.2019.11.047","volume":"38","author":"SC Pan","year":"2020","unstructured":"Pan, S. C. et al. A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(\u03b1K): a phase II study. Vaccine 38, 1048\u20131056 (2020).","journal-title":"Vaccine"},{"key":"2687_CR129","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3251","volume":"12","author":"N Lycke","year":"2012","unstructured":"Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592\u2013605 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2687_CR130","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0264-410X(99)00572-1","volume":"18","author":"JR Baldridge","year":"2000","unstructured":"Baldridge, J. R., Yorgensen, Y., Ward, J. R. & Ulrich, J. T. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18, 2416\u20132425 (2000).","journal-title":"Vaccine"},{"key":"2687_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109401","volume":"36","author":"B Zhao","year":"2021","unstructured":"Zhao, B. et al. A safe and effective mucosal RSV vaccine in mice consisting of RSV phosphoprotein and flagellin variant. Cell Rep. 36, 109401 (2021).","journal-title":"Cell Rep."},{"key":"2687_CR132","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/s41423-022-00929-3","volume":"19","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern. Cell. Mol. Immunol. 19, 1279\u20131289 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"2687_CR133","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.vaccine.2011.10.058","volume":"30","author":"SH Hong","year":"2012","unstructured":"Hong, S. H. et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine 30, 466\u2013474 (2012).","journal-title":"Vaccine"},{"key":"2687_CR134","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1128\/JVI.79.5.2910-2919.2005","volume":"79","author":"T Ichinohe","year":"2005","unstructured":"Ichinohe, T. et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79, 2910\u20132919 (2005).","journal-title":"J. Virol."},{"key":"2687_CR135","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.148494","volume":"6","author":"Y Sui","year":"2021","unstructured":"Sui, Y. et al. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight 6, e148494 (2021).","journal-title":"JCI Insight"},{"key":"2687_CR136","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1016\/j.vaccine.2014.07.078","volume":"32","author":"ET Overton","year":"2014","unstructured":"Overton, E. T. et al. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine 32, 5490\u20135495 (2014).","journal-title":"Vaccine"},{"key":"2687_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00399-0","volume":"6","author":"MM Abhyankar","year":"2021","unstructured":"Abhyankar, M. M. et al. Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant. NPJ Vaccines 6, 137 (2021).","journal-title":"NPJ Vaccines"},{"key":"2687_CR138","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1128\/CVI.00230-10","volume":"17","author":"LS Velasquez","year":"2010","unstructured":"Velasquez, L. S., Hjelm, B. E., Arntzen, C. J. & Herbst-Kralovetz, M. M. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin. Vaccine Immunol. 17, 1850\u20131858 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"2687_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105615","volume":"113","author":"K W\u00f8rzner","year":"2025","unstructured":"W\u00f8rzner, K. et al. Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection. EBioMedicine 113, 105615 (2025).","journal-title":"EBioMedicine"},{"key":"2687_CR140","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","volume":"21","author":"KP Hopfner","year":"2020","unstructured":"Hopfner, K. P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501\u2013521 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2687_CR141","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3389\/fimmu.2017.01223","volume":"8","author":"T Ebensen","year":"2017","unstructured":"Ebensen, T. et al. Mucosal administration of cycle-di-nucleotide-adjuvanted virosomes efficiently induces protection against influenza H5N1 in mice. Front. Immunol. 8, 1223 (2017).","journal-title":"Front. Immunol."},{"key":"2687_CR142","doi-asserted-by":"publisher","first-page":"e0005300","DOI":"10.1371\/journal.pntd.0005300","volume":"11","author":"MN Matos","year":"2017","unstructured":"Matos, M. N. et al. Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi. PLoS Negl. Trop. Dis. 11, e0005300 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2687_CR143","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/s41385-018-0080-x","volume":"11","author":"AC Allen","year":"2018","unstructured":"Allen, A. C. et al. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T(RM) cells. Mucosal Immunol. 11, 1763\u20131776 (2018).","journal-title":"Mucosal Immunol."},{"key":"2687_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103037","volume":"24","author":"X An","year":"2021","unstructured":"An, X. et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience 24, 103037 (2021).","journal-title":"iScience"},{"key":"2687_CR145","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3390\/biomedicines10051142","volume":"10","author":"T Jearanaiwitayakul","year":"2022","unstructured":"Jearanaiwitayakul, T. et al. The STING ligand and delivery system synergistically enhance the immunogenicity of an intranasal spike SARS-CoV-2 vaccine candidate. Biomedicines 10, 1142 (2022).","journal-title":"Biomedicines"},{"key":"2687_CR146","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0810","volume":"367","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 367, eaau0810 (2020).","journal-title":"Science"},{"key":"2687_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729189","volume":"12","author":"S Jangra","year":"2021","unstructured":"Jangra, S. et al. A combination adjuvant for the induction of potent antiviral immune responses for a recombinant SARS-CoV-2 protein vaccine. Front. Immunol. 12, 729189 (2021).","journal-title":"Front. Immunol."},{"key":"2687_CR148","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s13238-014-0125-1","volume":"6","author":"X Wang","year":"2015","unstructured":"Wang, X. & Meng, D. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes. Protein Cell 6, 170\u2013184 (2015).","journal-title":"Protein Cell"},{"key":"2687_CR149","doi-asserted-by":"publisher","first-page":"12703","DOI":"10.1128\/JVI.01182-10","volume":"84","author":"H Kayamuro","year":"2010","unstructured":"Kayamuro, H. et al. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J. Virol. 84, 12703\u201312712 (2010).","journal-title":"J. Virol."},{"key":"2687_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614115","volume":"12","author":"S Logerot","year":"2021","unstructured":"Logerot, S. et al. IL-7-adjuvanted vaginal vaccine elicits strong mucosal immune responses in non-human primates. Front. Immunol. 12, 614115 (2021).","journal-title":"Front. Immunol."},{"key":"2687_CR151","doi-asserted-by":"crossref","unstructured":"Hu, H. et al. Preliminary study on type I interferon as a mucosal adjuvant for human respiratory syncytial virus F protein. Vaccines 12, 1297 (2024).","DOI":"10.3390\/vaccines12111297"},{"key":"2687_CR152","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/0264-410X(92)90158-G","volume":"10","author":"M Cao","year":"1992","unstructured":"Cao, M., Sasaki, O., Yamada, A. & Imanishi, J. Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine 10, 238\u2013242 (1992).","journal-title":"Vaccine"},{"key":"2687_CR153","doi-asserted-by":"publisher","first-page":"e01262","DOI":"10.1128\/JVI.01262-19","volume":"93","author":"L Ye","year":"2019","unstructured":"Ye, L. et al. Type I and type III interferons differ in their adjuvant activities for influenza vaccines. J. Virol. 93, e01262\u201301219 (2019).","journal-title":"J. Virol."},{"key":"2687_CR154","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1016\/j.biomaterials.2009.07.009","volume":"30","author":"H Kayamuro","year":"2009","unstructured":"Kayamuro, H. et al. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials 30, 5869\u20135876 (2009).","journal-title":"Biomaterials"},{"key":"2687_CR155","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1016\/j.vaccine.2004.12.006","volume":"23","author":"L Bracci","year":"2005","unstructured":"Bracci, L. et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23, 2994\u20133004 (2005).","journal-title":"Vaccine"},{"key":"2687_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1153042","volume":"14","author":"K Chen","year":"2023","unstructured":"Chen, K. et al. Potentials of saponins-based adjuvants for nasal vaccines. Front. Immunol. 14, 1153042 (2023).","journal-title":"Front. Immunol."},{"key":"2687_CR157","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/vaccines2040686","volume":"2","author":"S Singh","year":"2014","unstructured":"Singh, S. et al. Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant. Vaccines 2, 686\u2013706 (2014).","journal-title":"Vaccines"},{"key":"2687_CR158","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.vaccine.2010.11.005","volume":"29","author":"YS Lee","year":"2011","unstructured":"Lee, Y. S. et al. An \u03b1-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine. Vaccine 29, 417\u2013425 (2011).","journal-title":"Vaccine"},{"key":"2687_CR159","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4049\/jimmunol.1800915","volume":"203","author":"G Zhou","year":"2019","unstructured":"Zhou, G., Hollenberg, M. D., Vliagoftis, H. & Kane, K. P. Protease-activated receptor 2 agonist as adjuvant: augmenting development of protective memory CD8 T cell responses induced by influenza virosomes. J. Immunol. 203, 441\u2013452 (2019).","journal-title":"J. Immunol."},{"key":"2687_CR160","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3390\/md18120605","volume":"18","author":"S Shim","year":"2020","unstructured":"Shim, S. & Yoo, H. S. The application of mucoadhesive chitosan nanoparticles in nasal drug delivery. Mar. Drugs 18, 605 (2020).","journal-title":"Mar. Drugs"},{"key":"2687_CR161","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nbt.2344","volume":"30","author":"F Wegmann","year":"2012","unstructured":"Wegmann, F. et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat. Biotechnol. 30, 883\u2013888 (2012).","journal-title":"Nat. Biotechnol."},{"key":"2687_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38066-8","volume":"14","author":"H Lei","year":"2023","unstructured":"Lei, H. et al. Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants. Nat. Commun. 14, 2678 (2023).","journal-title":"Nat. Commun."},{"key":"2687_CR163","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13115","volume":"81","author":"ER McColl","year":"2019","unstructured":"McColl, E. R. & Piquette-Miller, M. Poly(I:C) alters placental and fetal brain amino acid transport in a rat model of maternal immune activation. Am. J. Reprod. Immunol. 81, e13115 (2019).","journal-title":"Am. J. Reprod. Immunol."},{"key":"2687_CR164","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nm.1894","volume":"15","author":"MF Delgado","year":"2009","unstructured":"Delgado, M. F. et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15, 34\u201341 (2009).","journal-title":"Nat. Med."},{"key":"2687_CR165","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s41587-024-02486-8","volume":"42","author":"J Seo","year":"2024","unstructured":"Seo, J. et al. Challenges for developing broad-based mucosal vaccines for respiratory viruses. Nat. Biotechnol. 42, 1765\u20131767 (2024).","journal-title":"Nat. Biotechnol."},{"key":"2687_CR166","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","volume":"350","author":"M Mutsch","year":"2004","unstructured":"Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland. N. Engl. J. Med. 350, 896\u2013903 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2687_CR167","doi-asserted-by":"publisher","first-page":"e0139368","DOI":"10.1371\/journal.pone.0139368","volume":"10","author":"Y Fukuyama","year":"2015","unstructured":"Fukuyama, Y. et al. Nasal administration of cholera toxin as a mucosal adjuvant damages the olfactory system in mice. PLoS ONE 10, e0139368 (2015).","journal-title":"PLoS ONE"},{"key":"2687_CR168","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1073\/pnas.1104264108","volume":"108","author":"C Nembrini","year":"2011","unstructured":"Nembrini, C. et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc. Natl. Acad. Sci. USA 108, E989\u2013E997 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2687_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580974","volume":"11","author":"F Auderset","year":"2020","unstructured":"Auderset, F. et al. A TLR7\/8 agonist-including DOEPC-based cationic liposome formulation mediates its adjuvanticity through the sustained recruitment of highly activated monocytes in a type I IFN-independent but NF-\u03baB-dependent manner. Front. Immunol. 11, 580974 (2020).","journal-title":"Front. Immunol."},{"key":"2687_CR170","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","volume":"29","author":"D Smirnov","year":"2011","unstructured":"Smirnov, D., Schmidt, J. J., Capecchi, J. T. & Wightman, P. D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29, 5434\u20135442 (2011).","journal-title":"Vaccine"},{"key":"2687_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102172","volume":"70","author":"A Kaur","year":"2022","unstructured":"Kaur, A. et al. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr. Opin. Chem. Biol. 70, 102172 (2022).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2687_CR172","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41392-024-02025-6","volume":"9","author":"H Lei","year":"2024","unstructured":"Lei, H. et al. Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants. Signal Transduct. Target. Ther. 9, 311 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2687_CR173","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0264-410X(98)00252-7","volume":"17","author":"GL Barchfeld","year":"1999","unstructured":"Barchfeld, G. L. et al. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 17, 695\u2013704 (1999).","journal-title":"Vaccine"},{"key":"2687_CR174","doi-asserted-by":"publisher","first-page":"2492906","DOI":"10.1080\/21645515.2025.2492906","volume":"21","author":"LAA J","year":"2025","unstructured":"J, L. A. A. et al. Protein nanocages: a new frontier in mucosal vaccine delivery and immune activation. Hum. Vaccines Immunother. 21, 2492906 (2025).","journal-title":"Hum. Vaccines Immunother."},{"key":"2687_CR175","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/vaccines13060567","volume":"13","author":"T Tian","year":"2025","unstructured":"Tian, T. et al. FcRn-driven nanoengineered mucosal vaccine with multi-epitope fusion induces robust dual immunity and long-term protection against Brucella. Vaccines 13, 567 (2025).","journal-title":"Vaccines"},{"key":"2687_CR176","first-page":"799","volume":"34","author":"TR Cooney","year":"2023","unstructured":"Cooney, T. R. et al. Synthesis and biological evaluation of peptide-adjuvant conjugate vaccines with increasing antigen content. Bioconjug. Chem. 34, 799\u2013808 (2023).","journal-title":"Bioconjug. Chem."},{"key":"2687_CR177","doi-asserted-by":"publisher","first-page":"24650","DOI":"10.1021\/acsnano.3c10797","volume":"18","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Nanoplatform based intranasal vaccines: current progress and clinical challenges. ACS Nano 18, 24650\u201324681 (2024).","journal-title":"ACS Nano"},{"key":"2687_CR178","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2051013614541440","volume":"2","author":"RA Schwendener","year":"2014","unstructured":"Schwendener, R. A. Liposomes as vaccine delivery systems: a review of the recent advances. Therapeutic Adv. Vaccines 2, 159\u2013182 (2014).","journal-title":"Therapeutic Adv. Vaccines"},{"key":"2687_CR179","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/polym13071027","volume":"13","author":"V De Leo","year":"2021","unstructured":"De Leo, V., Milano, F., Agostiano, A. & Catucci, L. Recent advancements in polymer\/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polymers 13, 1027 (2021).","journal-title":"Polymers"},{"key":"2687_CR180","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1413","volume":"14","author":"BL Hartwell","year":"2022","unstructured":"Hartwell, B. L. et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci. Transl. Med. 14, eabn1413 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2687_CR181","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70093","volume":"19","author":"S Yahyaei","year":"2025","unstructured":"Yahyaei, S. et al. Targeting respiratory viruses: the efficacy of intranasal mRNA vaccination in generating protective mucosal and systemic immunity against influenza A (H1N1). Influenza Other Respir. Viruses 19, e70093 (2025).","journal-title":"Influenza Other Respir. Viruses"},{"key":"2687_CR182","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.intimp.2018.06.027","volume":"61","author":"R Tada","year":"2018","unstructured":"Tada, R. et al. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice. Int. Immunopharmacol. 61, 385\u2013393 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"2687_CR183","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jconrel.2015.04.010","volume":"208","author":"Y Fan","year":"2015","unstructured":"Fan, Y. et al. Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens. J. Control. Release 208, 121\u2013129 (2015).","journal-title":"J. Control. Release"},{"key":"2687_CR184","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1016\/j.vaccine.2009.05.032","volume":"27","author":"HX Sun","year":"2009","unstructured":"Sun, H. X., Xie, Y. & Ye, Y. P. ISCOMs and ISCOMATRIX. Vaccine 27, 4388\u20134401 (2009).","journal-title":"Vaccine"},{"key":"2687_CR185","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijpharm.2010.07.051","volume":"398","author":"RS Pandey","year":"2010","unstructured":"Pandey, R. S. et al. Evaluation of ISCOM matrices clearance from rabbit nasal cavity by \u03b3 scintigraphy. Int. J. Pharm.s 398, 231\u2013236 (2010).","journal-title":"Int. J. Pharm.s"},{"key":"2687_CR186","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3390\/vaccines9111350","volume":"9","author":"M Rivera-Patron","year":"2021","unstructured":"Rivera-Patron, M. et al. ISCOM-like nanoparticles formulated with Quillaja brasiliensis saponins are promising adjuvants for seasonal influenza vaccines. Vaccines 9, 1350 (2021).","journal-title":"Vaccines"},{"key":"2687_CR187","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3109\/21691401.2014.966195","volume":"44","author":"S Pabreja","year":"2016","unstructured":"Pabreja, S., Garg, T., Rath, G. & Goyal, A. K. Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes. Artif. Cells Nanomed. Biotechnol. 44, 532\u2013539 (2016).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"2687_CR188","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/10611860903450015","volume":"18","author":"RS Pandey","year":"2010","unstructured":"Pandey, R. S. & Dixit, V. K. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J. Drug Target. 18, 282\u2013291 (2010).","journal-title":"J. Drug Target"},{"key":"2687_CR189","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1046\/j.1365-2249.1998.00650.x","volume":"113","author":"KF Hu","year":"1998","unstructured":"Hu, K. F. et al. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin. Exp. Immunol. 113, 235\u2013243 (1998).","journal-title":"Clin. Exp. Immunol."},{"key":"2687_CR190","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/wnan.1364","volume":"8","author":"BL Banik","year":"2016","unstructured":"Banik, B. L., Fattahi, P. & Brown, J. L. Polymeric nanoparticles: the future of nanomedicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8, 271\u2013299 (2016).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"2687_CR191","doi-asserted-by":"publisher","first-page":"14341","DOI":"10.1039\/C6NR03256G","volume":"8","author":"N Islam","year":"2016","unstructured":"Islam, N. & Ferro, V. Recent advances in chitosan-based nanoparticulate pulmonary drug delivery. Nanoscale 8, 14341\u201314358 (2016).","journal-title":"Nanoscale"},{"key":"2687_CR192","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1007\/s12274-021-4012-9","volume":"15","author":"SH Zhuo","year":"2022","unstructured":"Zhuo, S. H. et al. A chitosan-mediated inhalable nanovaccine against SARS-CoV-2. Nano Res. 15, 4191\u20134200 (2022).","journal-title":"Nano Res."},{"key":"2687_CR193","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1021\/acsbiomaterials.2c01297","volume":"9","author":"S Manna","year":"2023","unstructured":"Manna, S. et al. Chitosan derivatives as carriers for drug delivery and biomedical applications. ACS Biomater. Sci. Eng. 9, 2181\u20132202 (2023).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"2687_CR194","doi-asserted-by":"publisher","first-page":"23739","DOI":"10.1074\/jbc.M110.126359","volume":"285","author":"TE Rajapaksa","year":"2010","unstructured":"Rajapaksa, T. E. et al. Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength. J. Biol. Chem. 285, 23739\u201323746 (2010).","journal-title":"J. Biol. Chem."},{"key":"2687_CR195","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-020-00434-x","volume":"5","author":"H Lei","year":"2020","unstructured":"Lei, H. et al. Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2. Signal Transduct. Target. Ther. 5, 291 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2687_CR196","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41392-022-01002-1","volume":"7","author":"H Lei","year":"2022","unstructured":"Lei, H. et al. Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants. Signal Transduct. Target Ther. 7, 159 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2687_CR197","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1021\/acs.molpharmaceut.0c00828","volume":"17","author":"M Comas-Garcia","year":"2020","unstructured":"Comas-Garcia, M., Colunga-Saucedo, M. & Rosales-Mendoza, S. The role of virus-like particles in medical biotechnology. Mol. Pharm. 17, 4407\u20134420 (2020).","journal-title":"Mol. Pharm."},{"key":"2687_CR198","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/all.15311","volume":"77","author":"DA Rothen","year":"2022","unstructured":"Rothen, D. A. et al. Intranasal administration of a virus like particles-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern. Allergy 77, 2446\u20132458 (2022).","journal-title":"Allergy"},{"key":"2687_CR199","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.virol.2013.03.027","volume":"442","author":"I Tretyakova","year":"2013","unstructured":"Tretyakova, I. et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology 442, 67\u201373 (2013).","journal-title":"Virology"},{"key":"2687_CR200","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1086\/657087","volume":"202","author":"SS El-Kamary","year":"2010","unstructured":"El-Kamary, S. S. et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202, 1649\u20131658 (2010).","journal-title":"J. Infect. Dis."},{"key":"2687_CR201","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jsps.2023.03.016","volume":"31","author":"H Ali","year":"2023","unstructured":"Ali, H. et al. Virosome: an engineered virus for vaccine delivery. Saudi Pharm. J. 31, 752\u2013764 (2023).","journal-title":"Saudi Pharm. J."},{"key":"2687_CR202","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3576028","volume":"2016","author":"M Pritsch","year":"2016","unstructured":"Pritsch, M. et al. Comparison of intranasal outer membrane vesicles with cholera toxin and injected MF59C.1 as adjuvants for malaria transmission blocking antigens AnAPN1 and Pfs48\/45. J. Immunol. Res. 2016, 3576028 (2016).","journal-title":"J. Immunol. Res."},{"key":"2687_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.781280","volume":"12","author":"PA van der Ley","year":"2021","unstructured":"van der Ley, P. A. et al. An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection. Front. Immunol. 12, 781280 (2021).","journal-title":"Front. Immunol."},{"key":"2687_CR204","doi-asserted-by":"publisher","first-page":"1029146","DOI":"10.3389\/fmicb.2022.1029146","volume":"13","author":"LA Lieberman","year":"2022","unstructured":"Lieberman, L. A. Outer membrane vesicles: a bacterial-derived vaccination system. Front. Microbiol. 13, 1029146 (2022).","journal-title":"Front. Microbiol."},{"key":"2687_CR205","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3390\/vaccines10101578","volume":"10","author":"D Kashyap","year":"2022","unstructured":"Kashyap, D. et al. Outer membrane vesicles: an emerging vaccine platform. Vaccines 10, 1578 (2022).","journal-title":"Vaccines"},{"key":"2687_CR206","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-023-06809-8","volume":"624","author":"T Ye","year":"2023","unstructured":"Ye, T. et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature 624, 630\u2013638 (2023).","journal-title":"Nature"},{"key":"2687_CR207","doi-asserted-by":"publisher","unstructured":"Hong, W. et al. Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01517-2 (2025).","DOI":"10.1038\/s41551-025-01517-2"},{"key":"2687_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00485-x","volume":"7","author":"SA Hameed","year":"2022","unstructured":"Hameed, S. A. et al. Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies. NPJ Vaccines 7, 71 (2022).","journal-title":"NPJ Vaccines"},{"key":"2687_CR209","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases\u2014advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2687_CR210","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jps.21077","volume":"97","author":"CA Squier","year":"2008","unstructured":"Squier, C. A., Mantz, M. J., Schlievert, P. M. & Davis, C. C. Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J. Pharm. Sci. 97, 9\u201321 (2008).","journal-title":"J. Pharm. Sci."},{"key":"2687_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2017.06.008","volume":"449","author":"TI de Silva","year":"2017","unstructured":"de Silva, T. I. et al. Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity. J. Immunol. Methods 449, 1\u20136 (2017).","journal-title":"J. Immunol. Methods"},{"key":"2687_CR212","doi-asserted-by":"publisher","unstructured":"Varadhachary, A. et al. Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. medRxiv [Preprint] https:\/\/doi.org\/10.1101\/2020.08.07.20170258 (2020).","DOI":"10.1101\/2020.08.07.20170258"},{"key":"2687_CR213","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","volume":"26","author":"M Liao","year":"2020","unstructured":"Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842\u2013844 (2020).","journal-title":"Nat. Med."},{"key":"2687_CR214","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.21037\/jtd-20-651","volume":"12","author":"KR Davidson","year":"2020","unstructured":"Davidson, K. R., Ha, D. M., Schwarz, M. I. & Chan, E. D. Bronchoalveolar lavage as a diagnostic procedure: a review of known cellular and molecular findings in various lung diseases. J. Thorac. Dis. 12, 4991\u20135019 (2020).","journal-title":"J. Thorac. Dis."},{"key":"2687_CR215","doi-asserted-by":"publisher","first-page":"e20220780","DOI":"10.1084\/jem.20220780","volume":"219","author":"JME Lim","year":"2022","unstructured":"Lim, J. M. E. et al. SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity. J. Exp. Med. 219, e20220780 (2022).","journal-title":"J. Exp. Med."},{"key":"2687_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30913-4","volume":"13","author":"A Ssemaganda","year":"2022","unstructured":"Ssemaganda, A. et al. Expansion of cytotoxic tissue-resident CD8(+) T cells and CCR6(+)CD161(+) CD4(+) T cells in the nasal mucosa following mRNA COVID-19 vaccination. Nat. Commun. 13, 3357 (2022).","journal-title":"Nat. Commun."},{"key":"2687_CR217","doi-asserted-by":"crossref","unstructured":"Gao, K. M. et al. Human nasal wash RNA-Seq reveals distinct cell-specific innate immune responses in influenza versus SARS-CoV-2. JCI Insight 6, e152288 (2021).","DOI":"10.1172\/jci.insight.152288"},{"key":"2687_CR218","doi-asserted-by":"publisher","first-page":"2475822","DOI":"10.1080\/22221751.2025.2475822","volume":"14","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. Exploring the standardization of human nasal antibody measurements. Emerg. Microbes Infect. 14, 2475822 (2025).","journal-title":"Emerg. Microbes Infect."},{"key":"2687_CR219","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-018-0072-y","volume":"38","author":"Y Nakamura","year":"2018","unstructured":"Nakamura, Y., Kimura, S. & Hase, K. M cell-dependent antigen uptake on follicle-associated epithelium for mucosal immune surveillance. Inflamm. Regener. 38, 15 (2018).","journal-title":"Inflamm. Regener."},{"key":"2687_CR220","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/vim.2012.0023","volume":"25","author":"SL Surman","year":"2012","unstructured":"Surman, S. L. et al. Vitamin A deficiency disrupts vaccine-induced antibody-forming cells and the balance of IgA\/IgG isotypes in the upper and lower respiratory tract. Viral Immunol. 25, 341\u2013344 (2012).","journal-title":"Viral Immunol."},{"key":"2687_CR221","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s41385-021-00413-7","volume":"14","author":"D Lin","year":"2021","unstructured":"Lin, D. et al. Crosstalk between the oral microbiota, mucosal immunity, and the epithelial barrier regulates oral mucosal disease pathogenesis. Mucosal Immunol. 14, 1247\u20131258 (2021).","journal-title":"Mucosal Immunol."},{"key":"2687_CR222","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.vaccine.2017.08.069","volume":"36","author":"P Zimmermann","year":"2018","unstructured":"Zimmermann, P. & Curtis, N. The influence of probiotics on vaccine responses \u2014a systematic review. Vaccine 36, 207\u2013213 (2018).","journal-title":"Vaccine"},{"key":"2687_CR223","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1111\/all.16174","volume":"79","author":"H Irizar","year":"2024","unstructured":"Irizar, H. et al. Multi-omic integration reveals alterations in nasal mucosal biology that mediate air pollutant effects on allergic rhinitis. Allergy 79, 3047\u20133061 (2024).","journal-title":"Allergy"},{"key":"2687_CR224","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/vaccines13040420","volume":"13","author":"L Montgomery","year":"2025","unstructured":"Montgomery, L. & Larbi, A. Monitoring immune responses to vaccination: a focus on single-cell analysis and associated challenges. Vaccines 13, 420 (2025).","journal-title":"Vaccines"},{"key":"2687_CR225","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.cell.2017.04.026","volume":"169","author":"S Li","year":"2017","unstructured":"Li, S. et al. Metabolic phenotypes of response to vaccination in humans. Cell 169, 862\u2013877.e817 (2017).","journal-title":"Cell"},{"key":"2687_CR226","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado8840","volume":"17","author":"R Nakahashi-Ouchida","year":"2025","unstructured":"Nakahashi-Ouchida, R. et al. Cationic nanogel-based nasal therapeutic HPV vaccine prevents the development of cervical cancer. Sci. Transl. Med. 17, eado8840 (2025).","journal-title":"Sci. Transl. Med."},{"key":"2687_CR227","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1016\/j.cell.2025.07.022","volume":"188","author":"K Haniuda","year":"2025","unstructured":"Haniuda, K. et al. Mucosal viral infection elicits long-lived IgA responses via type 1 follicular helper T cells. Cell 188, 6774\u20136790.e6721 (2025).","journal-title":"Cell"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02687-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:01:10Z","timestamp":1785110470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02687-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":227,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2687"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02687-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"301"}}